FOP

The FDA approved an oral drug, based on foundational research conducted at CHOP, to treat a rare, severe bone disease. More In The News.

Identified by CHOP researchers, palovarotene is the first drug approved (in Canada) for fibrodysplasia ossificans progressiva, a severe bone disease.

Many parents working in private sector are turning to Medicaid and CHIP for children’s healthcare coverage. This story and more In the News.

This week’s stories have elements that sound like fiction, but all are real, new scientific and medical findings: A condition that turns the body’s soft tissues into bone has new hope for a future treatment. Genetic superheroes walk among us, and they may not even know it. And pediatricians may have a tool to double their success in helping their patients’ parents quit smoking.